Finding a sirtuin truth in Huntington's disease.

Albert R La Spada

Abstract readNewsComment

In one paragraph

Article in Nature medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it

0cells of the map it votes in

9citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

Cerebellar Predominant Increase in mRNA Expression Levels of Sirt1 and Sirt3 Isoforms in a Transgenic Mouse Model of Huntington's Disease.Neurochemical research · 2020
Article
SIRT1 and SIRT2 Activity Control in Neurodegenerative Diseases.Frontiers in pharmacology · 2020
Review
Integration of the Deacetylase SIRT1 in the Response to Nucleolar Stress: Metabolic Implications for Neurodegenerative Diseases.Frontiers in molecular neuroscience · 2019
Article
Amelioration of Huntington's disease phenotypes by Beta-Lapachone is associated with increases in Sirt1 expression, CREB phosphorylation and PGC-1α deacetylation.PloS one · 2018
Article
Neurodegeneration Alters Metabolic Profile and Sirt 1 Signaling in High-Fat-Induced Obese Mice.Molecular neurobiology · 2017
Article
Sirtuins Expression and Their Role in Retinal Diseases.Oxidative medicine and cellular longevity · 2017
Review
Resveratrol: A Focus on Several Neurodegenerative Diseases.Oxidative medicine and cellular longevity · 2015
Review
SIRT1 in neurodevelopment and brain senescence.Neuron · 2014
Review
Sirtuin deacetylases in neurodegenerative diseases of aging.Cell research · 2013
Review

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Albert R La Spada

Funding

The PPAR-delta pathway in neural function and Huntington's disease neuropathologyR01NS065874 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LA SPADA, ALBERT R · 2010 to 2020

$4.0M

NINDS NIH HHS R01 NS065874

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsBrainCyclic AMP Response Element-Binding ProteinHumansHuntingtin ProteinHuntington DiseaseNerve Tissue ProteinsNeuronsNuclear ProteinsSirtuin 1Transcription FactorsCreb1 protein, mouseCrtc1 protein, mouseCyclic AMP Response Element-Binding ProteinHtt protein, mouseHuntingtin ProteinNerve Tissue ProteinsNuclear ProteinsSirt1 protein, mouseSirtuin 1Transcription Factors

Identifiers

PMID22227661

DOI10.1038/nm.2624

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.